Drugs / AT06A
last change May 2021 re-read 3 minutes ago

AT06A

Peptide

Developed for
hyperlipidemia
Investigated by
Affiris AG · Medical University of Vienna

Trials 1

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02508896 Jul 2015 → May 2016 hyperlipidemia Affiris AG Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as AT06A ClinicalTrials.gov intervention name — accepted as the source's own label NCT02508896 ↗
Modality Peptide “AT04A and AT06A are two AFFITOPE® peptide vaccine candidates” PMID 33969434 ↗ May 2021